Editorial: A unified view of ventricular remodelling

European Journal of Heart Failure

Volumn 12, Issue 8, 2010, Pages 779-781

  Shah, Amil M ^a   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MATRIX METALLOPROTEINASE;

CARDIAC RESYNCHRONIZATION THERAPY; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE WALL; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; WALL STRESS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HYPERTENSION; NOTE; PATHOLOGY; PATHOPHYSIOLOGY;

HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 77955443863     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq131     Document Type: Editorial

References (29)

1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
2. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infracted left ventricle of the rat. Circ Res 1985;57:84-95.
3. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica W, Khrakovskaya M, Arnold JMO, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005;111: 3411-3419.
4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;332:1561-1566.
5. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995;25:879-884.
6. Verma A, Meris A, Skali H, Ghali JK, Arnold JMO, Bourgoun M, Velazquez EJ, McMurray JJV, Kober L, Pfeffer MA, Califf RM, Solomon SD. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (Valsartan in acute myocardial infarction) echocardiographic study. JACC Cardiovasc Imaging 2008;1:582-591.
7. Jilaihawi H, Greaves S, Rouleau JL, Pfeffer MA, Solomon SD. Left ventricular hypertrophy and the risk of subsequent left ventricular remodeling following myocardial infarction. Am J Cardiol 2003;91:723-726.
8. Murcia AM, Hennekens CH, Lamas GA, Jimenez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004;164:2273-2279.
9. Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJV, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Hypertension 2008;51:48-54.
10. Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moyé L, Braunwald E, Pfeffer MA, Survival and Ventricular Enlargement (SAVE) Investigators. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002; 106:1251-1255.
11. Carrabba N, Valenti R, Parodi G, Santoro GM, Antoniucci D. Left ventricular remodeling and heart failure in diabetic patients treated with primary angioplasty for acute myocardial infarction. Circulation 2004;110:1974-1979.
12. Mann D, Bogaev R, Buckberg G. Cardiac remodelling and myocardial recovery: lost in translation. Eur J Heart Fail 2010;12:789-796.
13. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, Keulenaer GD, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
14. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738-3744.
15. Solomon SD, Glynn RJ, Greaves S, Ajanl U, Rouleau JL, Menapace F, Arnold JMO, Hennekens C, Pfeffer MA. Recovery of ventricular function after myocardial infarction in the reperfusion era: the Healing and Early Afterload Reducing Therapy study. Ann Intern Med 2001;134:451-458.
16. Schachinger V, Assmus B, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Yu J, Corti R, Mathey DG, Hamm CW, Tonn T, Dimmeler S, Zeiher AM. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodeling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail 2009;11:973-979.
17. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81: 1161-1172.
18. Hauptman PJ, Sabbah HN. Reversal of ventricular remodeling: important to establish and difficult to define. Eur J Heart Fail 2007;9:325-328.
19. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown M, Hall WJ, Pfeffer MA, Moss AJ. Effect of cardiac resynchronization therapy on reverse remodeling and outcome. Circulation 2010 (in press).
20. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-2356.
21. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005;111:2837-2849.
22. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000;15: 264-272.
23. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002;346:1357-1365.
24. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 2006;12:277-1239
25. Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, Geelen P, Verstreken S, Wellens F, Bartunek J. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 2008;51:129-136.
26. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-677.
27. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NAM, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361.
28. Di Donato M, Castelvecchio S, Menicanti L. End-systolic volume following surgical ventricular reconstruction impacts survival in patients with ischemic dilated cardiomyopathy. Eur J Heart Fail 2010;12:375-381.
29. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.